Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)
Status:
Withdrawn
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Participants will be randomized (1:1) to one of two sequences of a vaginal ring (VR)
containing 25mg of dapivirine to be inserted monthly for 24 weeks and 200 mg FTC/300 mg TDF
oral tablets taken daily for 24 weeks. After completing the randomized sequence of two study
product use periods, participants will then select between the two study products to use in
the final 24 weeks of the trial. Participants will be able to choose either or neither study
product every 4 weeks during the third product use period.
Phase:
Phase 2
Details
Lead Sponsor:
International Partnership for Microbicides, Inc.
Collaborator:
Gilead Sciences
Treatments:
Dapivirine Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir